Can Fite Biofarma (STU:CF5) ROCE % : -97.31% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Can Fite Biofarma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Can Fite Biofarma's annualized ROCE % for the quarter that ended in Dec. 2023 was -97.31%.

Can Fite Biofarma ROCE % Historical Data

The historical data trend for Can Fite Biofarma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma ROCE % Chart

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-249.53

-207.57

-101.96

-87.01

-109.64

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-141.86	-124.32	-73.11	-95.51	-97.31

Can Fite Biofarma ROCE % Calculation

Can Fite Biofarma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-7.515	/	( ( (8.763 - 2.362)	+	(9.16 - 1.852) )	/ 2 )
	=	-7.515	/	( (6.401	+	7.308)	/ 2 )
	=	-7.515	/	6.8545
	=	-109.64 %

Can Fite Biofarma's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-6.728	/	( ( (8.591 - 2.071)	+	(9.16 - 1.852) )	/ 2 )
	=	-6.728	/	( ( 6.52	+	7.308 )	/ 2 )
	=	-6.728	/	6.914
	=	-97.31 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Can Fite Biofarma (STU:CF5) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Can Fite Biofarma ROCE % Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (STU:CF5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (STU:CF5) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CANF:USA CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (STU:CF5) Headlines

No Headlines